Price T Rowe Associates Inc Exelixis, Inc. Transaction History

Price T Rowe Associates Inc

$816 Billion
Q1 2024

A detailed history of Price T Rowe Associates Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,338,238 shares of EXEL stock, worth $75 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,338,238

Previous 3,649,673 8.53%

Holding current value

$75 Million

Previous $87.6 Million 9.52%

% of portfolio

0.01%

Previous 0.01%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$20.17 - $23.93 $6.28 Million - $7.45 Million	-311,435 Reduced 8.53%	3,338,238 $79.2 Million
Q4 2023 Feb 14, 2024	SELL	$19.25 - $24.13 $15.8 Million - $19.9 Million	-823,151 Reduced 18.4%	3,649,673 $87.6 Million
Q3 2023 Nov 14, 2023	SELL	$19.04 - $22.74 $9.06 Million - $10.8 Million	-475,990 Reduced 9.62%	4,472,824 $97.7 Million
Q2 2023 Aug 14, 2023	SELL	$18.17 - $20.48 $19.3 Million - $21.8 Million	-1,063,974 Reduced 17.7%	4,948,814 $94.6 Million
Q1 2023 May 15, 2023	SELL	$16.3 - $19.41 $10 Million - $11.9 Million	-615,102 Reduced 9.28%	6,012,788 $117 Million

Q4 2022 Feb 14, 2023	SELL	$14.96 - $17.39 $20.9 Million - $24.3 Million	-1,395,152 Reduced 17.39%	6,627,890 $106 Million
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $84.7 Million - $120 Million	-5,401,973 Reduced 40.24%	8,023,042 $126 Million
Q2 2022 Aug 15, 2022	SELL	$17.44 - $23.16 $41 Million - $54.4 Million	-2,348,770 Reduced 14.89%	13,425,015 $280 Million
Q1 2022 May 16, 2022	SELL	$17.03 - $22.67 $22.6 Million - $30.1 Million	-1,326,182 Reduced 7.76%	15,773,785 $358 Million
Q4 2021 Feb 14, 2022	SELL	$15.84 - $21.88 $2.17 Million - $3 Million	-137,168 Reduced 0.8%	17,099,967 $313 Million
Q3 2021 Nov 15, 2021	SELL	$16.3 - $21.14 $39.7 Million - $51.5 Million	-2,438,405 Reduced 12.39%	17,237,135 $364 Million
Q2 2021 Aug 16, 2021	SELL	$17.95 - $25.56 $19 Million - $27.1 Million	-1,058,798 Reduced 5.11%	19,675,540 $358 Million
Q1 2021 May 17, 2021	BUY	$20.53 - $25.22 $64.6 Million - $79.3 Million	3,145,844 Added 17.89%	20,734,338 $468 Million
Q4 2020 Feb 16, 2021	BUY	$18.39 - $24.8 $323 Million - $436 Million	17,588,494 New	17,588,494 $353 Million

Others Institutions Holding EXEL

# of Institutions

459

Shares Held

246M

Call Options Held

1.7M

Put Options Held

1.02M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $7.23B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Exelixis, Inc. Transaction History